One big caution is that Parkinsons trials are notoriously tricky - there can be a big placebo effect and there have been a litany of failed Phase IIIs after successful Phase IIs:
Here it is a bit worrying that "average total daily time of troublesome dyskinesia was not increased in one group and was decreased by 42% in the second group" - that perhaps suggests something going on with their trial design.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.